# A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

> **NCT01676259** · PHASE2 · UNKNOWN · sponsor: **Silenseed Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** siG12D-LODER
- **DRUG:** Gemcitabine+nab-Paclitaxel
- **DRUG:** Folfirinox

## Key facts

- **NCT ID:** NCT01676259
- **Lead sponsor:** Silenseed Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-07
- **Primary completion:** 2022-10
- **Final completion:** 2023-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676259, "A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01676259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*